Mar. 31 at 1:34 PM
$INKT what I like particularly here is the unusual transitioning from AGEN subsidiary to full-fledged bio before our very eyes. We have an opportunity to invest at a stage where usually everything is kept private, with rounds of A, B, C series..
With the depth of the projects, and the obvious behind-the-scene action involving IBRX, talk of R&D day, etc, there's a very good chance this is trading at
$300M+ MC before year end
